TNFRSF17 and Miyoshi myopathy: Relapses may be due to a number of factors including heterogenous and/or low pre-treatment expression of BCMA by fully differentiated tumor cells4, absence of BCMA from less differentiated MM cells, and loss of BCMA expression under the selective pressure of the CAR T cell-mediated immune response2.